PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
AxoGen, Inc. (AXGN)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS05463X1063
CUSIP05463X106
SectorHealthcare
IndustryMedical Devices

Highlights

Market Cap$283.97M
EPS-$0.51
Revenue (TTM)$159.01M
Gross Profit (TTM)$114.44M
EBITDA (TTM)-$16.97M
Year Range$3.45 - $10.83
Target Price$13.67
Short %4.25%
Short Ratio4.81

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


AxoGen, Inc.

Popular comparisons: AXGN vs. SPY

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in AxoGen, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%50.00%100.00%150.00%NovemberDecember2024FebruaryMarchApril
74.12%
17.96%
AXGN (AxoGen, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

AxoGen, Inc. had a return of 0.44% year-to-date (YTD) and -27.94% in the last 12 months. Over the past 10 years, AxoGen, Inc. had an annualized return of 9.36%, while the S&P 500 had an annualized return of 10.42%, indicating that AxoGen, Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date0.44%5.05%
1 month-6.67%-4.27%
6 months76.35%18.82%
1 year-27.94%21.22%
5 years (annualized)-20.27%11.38%
10 years (annualized)9.36%10.42%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
202441.58%9.20%-23.58%
2023-20.13%-24.80%74.20%4.27%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of AXGN is 28, suggesting that the investment has average results relative to the market in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.

The Risk-Adjusted Performance Rank of AXGN is 2828
AxoGen, Inc.(AXGN)
The Sharpe Ratio Rank of AXGN is 2828Sharpe Ratio Rank
The Sortino Ratio Rank of AXGN is 2929Sortino Ratio Rank
The Omega Ratio Rank of AXGN is 2929Omega Ratio Rank
The Calmar Ratio Rank of AXGN is 3030Calmar Ratio Rank
The Martin Ratio Rank of AXGN is 2424Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for AxoGen, Inc. (AXGN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


AXGN
Sharpe ratio
The chart of Sharpe ratio for AXGN, currently valued at -0.46, compared to the broader market-2.00-1.000.001.002.003.00-0.46
Sortino ratio
The chart of Sortino ratio for AXGN, currently valued at -0.39, compared to the broader market-4.00-2.000.002.004.00-0.39
Omega ratio
The chart of Omega ratio for AXGN, currently valued at 0.95, compared to the broader market0.501.001.500.95
Calmar ratio
The chart of Calmar ratio for AXGN, currently valued at -0.34, compared to the broader market0.001.002.003.004.005.00-0.34
Martin ratio
The chart of Martin ratio for AXGN, currently valued at -1.08, compared to the broader market0.0010.0020.0030.00-1.08
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.81, compared to the broader market-2.00-1.000.001.002.003.001.81
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.64, compared to the broader market-4.00-2.000.002.004.002.64
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.31, compared to the broader market0.501.001.501.32
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.38, compared to the broader market0.001.002.003.004.005.001.38
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.21, compared to the broader market0.0010.0020.0030.007.21

Sharpe Ratio

The current AxoGen, Inc. Sharpe ratio is -0.46. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
-0.46
1.81
AXGN (AxoGen, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


AxoGen, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-87.73%
-4.64%
AXGN (AxoGen, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the AxoGen, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the AxoGen, Inc. was 98.50%, occurring on Aug 16, 2002. Recovery took 2992 trading sessions.

The current AxoGen, Inc. drawdown is 87.73%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.5%Jun 10, 19961393Aug 16, 20022992May 1, 20174385
-93.54%Jul 24, 20181329Nov 1, 2023
-57.14%Sep 25, 1989295Jan 17, 199195Jun 5, 1991390
-52.46%Aug 28, 1991168Apr 28, 1992713Apr 17, 1995881
-43.4%Sep 29, 198720Oct 26, 1987456Sep 21, 1989476

Volatility

Volatility Chart

The current AxoGen, Inc. volatility is 14.41%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%NovemberDecember2024FebruaryMarchApril
14.41%
3.30%
AXGN (AxoGen, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of AxoGen, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items